SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rolf Schoch who wrote ()3/13/2000 4:25:00 PM
From: scott_jiminez  Read Replies (1) of 4474
 
From Smcps onln today:

'We have received many calls and e-mails related to CEO Harvey Berger's appearance on CNBC's 'Squawk Box' March 3, 2000. Many of our subscribers may have mis-interpreted Dr. Berger's comments concerning the ARIA revenue model. Like most gene therapy companies, the size and timing of ARIA's product revenues and earnings are extremely difficult to predict. However, partnership and licensing agreements offer ARIA a source of near-term revenue, and we anticipate ARIA having multiple opportunities to partner its ARGENT and RAPID systems in the next 6 to 24 months or to license the technology to pharmaceutical or biotechnology companies. We are confident that the recent high profile Science paper illustrating the power of RAPID technology, has triggered significant industry interest. We are reiterating our BUY rating on ARIA and recommend purchase of stock for those investors tolerant of the risks associated with small cap stocks.'

Their emphasis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News